Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2016

View Archived Issues

Immunomedics terminates phase III PANCRIT-1 trial for clivatuzumab tetratexan

Adocia and Lilly present positive topline results from phase Ib study of BioChaperone Lispro

CTxT Pty patents PRMT5 inhibitors

Pierre Fabre describes FLT3, JAK2 and/or JAK3 inhibitors

NicOx patent discloses nitric oxide donors

CHDI Foundation divulges probes for imaging huntingtin protein

Blueprint Medicines and Roche enter worldwide collaboration in the field of cancer immunotherapy

Shionogi presents AMPK activators

HUYA Bioscience licenses ex-China rights to IDO inhibitors from Fudan University

Safety, tolerability and pharmacokinetics of LCB01-0371 in healthy volunteers

Aralez resubmits Yosprala NDA

Novel dual-target compounds inhibit inducible nitric oxide synthase and cannabinoid CB1 receptors

Orexigen announces strategic acquisition of all rights to Contrave in the U.S.

Takeda Pharmaceuticals U.S.A. announces new U.S. strategy and organization

Verona Pharma announces positive results from RPL-554 trial in asthma

ViDAC Pharma describes first-in-class VDAC/HK modulator for skin cancer

PF-06747775: a third-generation EGFR tyrosine kinase inhibitor

Xenon updates progress of pain collaborations with Genentech

ProMetic Life Sciences to explore use of PBI-4050 for scleroderma

Phase III data on padeliporfin di-potassium in low-risk prostate cancer

Boehringer Ingelheim seeks Japanese approval of idarucizumab in Japan

DSMB recommends continuation of phase II trial of lirilumab in elderly patients with AML

Regulatory agencies review Zydelig over serious adverse events in ongoing trials

18F-FACBC tracer as alternative to 11C-choline imaging in prostate cancer relapse

Johnson & Johnson launches JLINX, a new platform to promote scientific innovation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...